worth buying post Earnings results? NASDAQ:NODK, NASDAQ:TCRR, NASDAQ:PBPB, NASDAQ:PIRS

NI EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:NODK)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN NI? (NASDAQ:NODK)

Wall Street analysts have given NI a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NI wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.

TCR2 THERAPEUTICS (NASDAQ:TCRR) EARNINGS INFORMATION (NASDAQ:TCRR)

TCR2 Therapeutics last announced its quarterly earnings data on March 11th, 2021. The reported ($0.55) earnings per share for the quarter, meeting the consensus estimate of ($0.55). TCR2 Therapeutics has generated ($4.62) earnings per share over the last year. TCR2 Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, May 13th, 2021 based off prior year’s report dates.

IS TCR2 THERAPEUTICS A BUY RIGHT NOW? (NASDAQ:TCRR)

8 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for TCR2 Therapeutics in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” TCR2 Therapeutics stock.
TCR2 Therapeutics

POTBELLY (NASDAQ:PBPB) EARNINGS INFORMATION (NASDAQ:PBPB)

Potbelly last posted its quarterly earnings data on March 10th, 2021. The reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.17. Potbelly has generated ($0.10) earnings per share over the last year. Potbelly has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, May 11th, 2021 based off prior year’s report dates.

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN POTBELLY? (NASDAQ:PBPB)

Wall Street analysts have given Potbelly a “N/A” rating, but there may be better short-term opportunities in the market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Potbelly wasn’t one of them. MarketBeat thinks these five stocks may be even better buys.

PIERIS PHARMACEUTICALS EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NASDAQ:PIRS)

IS PIERIS PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:PIRS)

3 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Pieris Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” Pieris Pharmaceuticals stock.
Pieris Pharmaceuticals